INHIBITORS OF ENZYMES CONVERTING 1beta-INTERLEUKIN

FIELD: organic chemistry, biochemistry, medicine. SUBSTANCE: invention relates to compounds of the general formulas alpha- and beta-: and , wherein n = 0, 1 or 2; m and m' represent 1 or 2; R11 means: or ; R2' = R2 is hydrogen atom; R3 is -CH2Ar or 5-15-membered nonaromatic monocyclic group that can comprise from 0 to 2 endocyclic nitrogen atoms; R4 is unbranched (C1-5)-alkyl group; R5 is taken among group including -C(0)R7, -C(0)OR9, -C(0)C(0)R7; R7 is taken among the group: phenyl, naphthyl, isoquinoline being phenyl can be substituted with halogen atom, (C1-6)-alkoxy group, 1,2-methylenedioxy-group or N(H)C(O)-(C1-6)-alkyl; R9 is taken independently among direct -alkyl group optionally substituted with phenyl; R12 and R13 are taken independently among the group including R7, -C(O)-R7 and C(O)-N(H)-R7; or R12 and R13 form in common 4-8-membered saturated cyclic group. Invention relates to pharmaceutical composition used for inhibition of activity of enzyme converting 1beta-interleukin (ICE), to method for inhibition of activity of ICE, to methods for treatment or prophylaxis of IL-mediated diseases. EFFECT: valuable medicinal properties of compounds. 14 cl, 1 tbl